Ruxolitinib + Placebo
Phase 3Completed 2 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cytokine Storm (Covid-19)
Conditions
Cytokine Storm (Covid-19)
Trial Timeline
May 2, 2020 → Oct 17, 2020
NCT ID
NCT04362137About Ruxolitinib + Placebo
Ruxolitinib + Placebo is a phase 3 stage product being developed by Novartis for Cytokine Storm (Covid-19). The current trial status is completed. This product is registered under clinical trial identifier NCT04362137. Target conditions include Cytokine Storm (Covid-19).
What happened to similar drugs?
0 of 1 similar drugs in Cytokine Storm (Covid-19) were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04362137 | Phase 3 | Completed |
Competing Products
3 competing products in Cytokine Storm (Covid-19)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Canakinumab + Placebo | Novartis | Phase 3 | 40 |
| canakinumab | Novartis | Pre-clinical | 26 |
| Itacitinib + Immune effector cell therapy + Placebo + Yescarta | Incyte | Phase 2 | 32 |